Wells Fargo analyst Tim Evans believes speculation of Thermo Fisher (TMO) acquiring Illumina "makes no sense." The analyst estimates the deal would be about 14% dilutive to Thermo in year one and "would struggle to be neutral" to earnings by year three. Further, the deal would run into "significant regulatory hurdles" since that Illumina holds a near monopoly in high-throughput sequencing, Evans tell investors note. Shares of Illumina are off their highs but remain up 3% after StreetInsider stoked renewed takeout speculation by citing a source saying Thermo may bid $30B for the company.